FLT3 and nutritional disorder: Overall, haematological AEs, metabolism and nutritional disorders, gastrointestinal disorders and constitutional symptoms were not significantly different between FLT3 inhibitor and control groups (RR = 1.03, 95% CI 1.00 to 1.07, p = 0.06, I2 = 51%, Supplementary Figure 16; RR = 1.10, 95% CI 0.86 to 1.41, p = 0.46, I2 = 17%, Supplementary Figure 17; RR = 1.07, 95% CI 0.88 to 1.29, p = 0.51, I2 = 35%, Supplementary Figure 18; RR = 1.05, 95% CI 0.95 to 1.17, p = 0.35, I2 = 0%, Supplementary Figure 19, respectively).